Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its flagship product, Contrave, a weight-loss medication, according to CEO George ...
Donald Trump’s attempt to align foreign aid with his America First policy is too blunt and will have deadly consequences.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback